Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with placebo.